RANCHO CORDOVA, Calif., Feb. 05, 2018 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Chris Xu, Ph.D., chief executive officer, will be presenting at the BIO CEO & Investor Conference on Monday, February 12, 2018 at 2:30pm EST. The conference is being held February 12-13 at the New York Marriott Marquis.
About Cesca Therapeutics Inc.
Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Cesca is also leveraging its proprietary AutoXpress® technology platform to develop an automated, functionally-closed CAR-TXpress platform that addresses cellular manufacturing needs in the immuno-oncology field.
Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
ir@cescatherapeutics.com
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
pschwartz@rxir.com
